ABUS logo

ABUS Arbutus Biopharma Corp

NASDAQ · Biotechnology · Healthcare

$4.67
+0.09 (+1.97%)

Arbutus Biopharma Corporation, a clinical-stage biopharmaceutical company, develops novel therapeutics for infectious disease in the United States. Its chronic Hepatitis B virus product pipeline comprises Imdusiran, conjugated GalNAc, subcutaneously-delivered RNAi therapeutic product candidate which is in phase 2a clinical trials that suppresses all HBV antigens, including HBsAg expression; and AB…

Market Cap: $922.50Mwww.arbutusbio.com

Price (90d)

No price history yet — the daily price refresh runs once a day.

Signal Score (90d)

120
120
Aug 12Aug 12

Quote

Day Range
$4.55 – $4.71
52-Week Range
$3.35 – $5.38
Volume
$1.44M
Market Cap
$922.50M
50-Day Avg
$4.54
200-Day Avg
$4.46
Prev Close
$4.58
Open
$4.59

Valuation & Ratios

P/E Ratio
-28.29
EPS
$-0.17
P/B Ratio
12.04
P/S Ratio
65.44
Debt/Equity
0.05
Current Ratio
15.73
Dividend Yield
+0.0%
Gross Margin
+97.4%

Returns & Efficiency

Return on Equity
-43.7%
Return on Assets
-35.4%
FCF Yield
-4.3%
EV/EBITDA
-27.47

Revenue & Net Income (Annual)

Fiscal YearRevenueNet IncomeEPS
2025$14.08M$-33.50M$-0.17
2024$6.17M$-69.92M$-0.38
2023$18.14M$-72.85M$-0.44
2022$39.02M$-69.46M$-0.46
2021$10.99M$-76.25M$-0.73

Social Signal Score

70
5d
70
1 mentions
30d
70
1 mentions
60d
70
1 mentions
90d
70
1 mentions
news: 1

Earnings

Wed, Nov 11(in 3 months)

Consensus estimate $-0.02 per share

5of 7 quarters beat consensus

Typical surprise +28.6% (median, so one quarter with a near-zero estimate can't distort it)

  • Wed, Aug 12$-0.03 vs $-0.02miss
  • Wed, May 13$0.87 vs $-0.03beat
  • Mon, Mar 23$-0.01 vs $-0.04beat
  • Thu, Nov 13$-0.04 vs $-0.06beat
  • Wed, Aug 6$0.01 vs $-0.02beat
  • Wed, May 14$-0.13 vs $-0.09miss

Estimates and results for ABUS via Financial Modeling Prep. Beating consensus says the company cleared the bar analysts set, not that the business grew.

Valuation

ABUShas no positive reported earnings per share, so an earnings-multiple projection can't be built for it. Companies are valued on other measures at this stage — revenue growth, cash burn, or book value — none of which this calculator models.

Mentions (1)

  • Newsglobenewswire.com·3d ago·Positive

    Arbutus Reports Second Quarter 2026 Financial Results and Provides Corporate Update Maintained strong financial position with cash, cash equivalents and marketable securities of $92.6M as of June 30, 2026

    View source ↗